Vastra Frolunda, Sweden

Bengt Gustavsson

This inventor holds 18 USPTO granted patents and 2 published patent applications and 5 EPO patents, primarily in Chemotherapy Innovations. Top assignees: Isofol Medical Ab, University of Southern California, Other. Active years: 1983-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bengt Gustavsson. Retrieved from https://idiyas.com/inventor/bengt-gustavsson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 83.3

 

Average Co-Inventor Count = 2.3

ph-index = 7

Forward Citations = 1,164(Granted Patents)


Location History:

  • Vastra Frolunda, SE (1983 - 1986)
  • 79 Vastra Frolunda, SE (1987 - 1990)
  • Gothenburg, SE (1994)
  • Goteborg, SE (1986 - 1996)
  • Västra Frölunda, SE (2015 - 2017)
  • Västra Froelunda, SE (2019 - 2022)

Company Filing History:


Years Active: 1983-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
5-Fluorouracil
Folate Alternative
Thymidylate Synthase
Tetrahydrofolates
Antifolates
Chemotherapeutic Modulator
Vessel Handling
Fluid Transfer
Catheter-Cannula
Sterile Storage
Dispensing Container
18 patents (USPTO):Explore Patents

Title: The Innovations of Bengt Gustavsson

Introduction

Bengt Gustavsson is a notable inventor based in Vastra Frolunda, Sweden. He has made significant contributions to the field of medical science, particularly in cancer treatment. With a total of 17 patents to his name, his work has had a profound impact on therapeutic methods.

Latest Patents

Gustavsson's latest patents include innovative methods for increasing blood plasma 2'-deoxyuridine (dUrd) and thymidylate synthase inhibition. The present invention provides methods for increasing plasma dUrd levels through the administration of 6R-MTHF. These methods enhance dUrd levels compared to equimolar concentrations of LV. Additionally, he has developed methods for increasing TS inhibition, also involving the administration of 6R-MTHF. Another significant patent relates to the use of [6R]-5,10-methylenetetrahydrofolate as an efficient folate alternative in 5-fluorouracil based chemotherapy, particularly for treating solid tumors such as colorectal cancer.

Career Highlights

Throughout his career, Bengt Gustavsson has worked with various companies, including Isofol Medical AB. His innovative approaches have positioned him as a key figure in the development of new cancer therapies.

Collaborations

Gustavsson has collaborated with notable individuals in his field, including Göran U Carlsson and Anders Vedin. These partnerships have furthered his research and contributed to his success as an inventor.

Conclusion

Bengt Gustavsson's contributions to medical science through his patents and collaborations highlight his dedication to improving cancer treatment. His innovative methods continue to pave the way for advancements in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…